In the News

---

An Oral Approach for Diabetic Retinopathy

05 August 2025
The Medicine Maker
View Story

---

Phase Ib trial complete in patients with diabetic retinopathy

27 June 2025
Drug Discovery World (DDW)
View Story

---

An oral treatment for diabetic retinopathy

26 June 2025
Association of Optometrists (AOP)
View Story

---

Biotekselskab får positive resultater med lægemiddelhåb mod øjensygdomme

25 June 2025
MedWatch.dk
View Story [Behind paywall – Danish Language]

---

Breye Therapeutics has First patient dosed in phase 1b/2a trial of oral danegaptide for diabetic retinopathy

26 Jan 2024
Healio
View Story

---

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

25 January 2024
PharmiWeb
View Story

---

The oral therapeutic that could change our approach to retinal disease

13 Oct 2023
Ophthalmology Times Europe
View Story

---

Golgi and Breye partner to develop P2X7 receptor antagonist programme

25 July 2023
Pharmaceutical Technology
View Story

---

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

25 July 2023
BioWorld
View Story [Behind Paywall]

---

Five ophthalmology biotech companies to look out for

1 June 2023
Labiotech
View Story

---

Breye Therapeutics Strengthens Management Team and Board

20 April 2023
FirstWord Pharma
View Story

---

Oral alternative to eye injections? Novo backs startup’s big plan to repurpose shelved drug

10 Nov 2022
Endpoints
View Story [Behind Paywall]

---

Breye launched to develop oral therapy for diabetic retinopathy

10 Nov 2022
BioWorld
View Story [Behind Paywall]

---